Nita Nicoleta, Felbel Dominik, Paukovitsch Michael, von Sanden Felix, Walter Elene, Melnic Rima, Rottbauer Wolfgang, Buckert Dominik, Mörike Johannes
Department of Internal Medicine II, University Medical Center, 89081 Ulm, Germany.
Biomedicines. 2025 May 16;13(5):1211. doi: 10.3390/biomedicines13051211.
: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), the effect of tafamidis on right ventricular (RV) dysfunction has been poorly investigated. The purpose of this study was to evaluate the effect of tafamidis on RV free wall global longitudinal strain (RV FW-GLS) and right ventricular and pulmonary artery (RV-PA) coupling over 12 months of treatment. : Ninety-three patients with ATTR-CM treated with 61 mg of tafamidis daily who underwent multimodality imaging evaluation at baseline by cardiovascular magnetic resonance (CMR) and speckle-tracking echocardiography were retrospectively studied. The 12-month follow-up included an echocardiographic assessment of RV FW-GLS and RV-PA coupling. RV reverse remodeling was defined as a >10% improvement in RV FW-GLS and/or in RV-PA coupling from baseline. RV-PA coupling was assessed using the tricuspid annular plane systolic excursion/ pulmonary artery systolic pressure (TAPSE/PASP) ratio. : Over 12 months of tafamidis treatment, RV reverse remodeling was documented in 22.6% of patients. In these patients, RV FW-GLS improved significantly from 14.5 ± 2.1% to 17.3 ± 2%, < 0.001, whereas the TAPSE/PASP ratio improved from 0.42 ± 0.05 mm/mmHg to 0.54 ± 0.07 mm/mmHg, = 0.001. Patients who experienced RV reverse remodeling were at an earlier stage of disease prior to tafamidis treatment with less dilated RV and less severe RV-PA uncoupling (TAPSE/PASP ratio: 0.43 ± 0.06 mm/mmHg vs. 0.39 ± 0.06 mm/mmHg, = 0.040). CMR-derived baseline RV end-systolic volume (HR 0.83, 95% CI 0.73-0.94, = 0.005) and NT-proBNP (HR 0.989, 95% CI 0.988-0.999, = 0.024) were the strongest independent predictors of RV reverse remodeling, followed by PASP (HR 0.82, 95% CI 0.69-0.98, = 0.030). : Patients with ATTR-CM treated with tafamidis at an earlier stage of the disease experienced RV reverse remodeling with significant improvement in RV FW-GLS and RV-PA coupling.
在转甲状腺素蛋白淀粉样心肌病(ATTR-CM)患者中,他法米地对右心室(RV)功能障碍的影响尚未得到充分研究。本研究的目的是评估他法米地在12个月治疗期内对右心室游离壁整体纵向应变(RV FW-GLS)以及右心室与肺动脉(RV-PA)耦联的影响。:对93例接受每日61毫克他法米地治疗的ATTR-CM患者进行回顾性研究,这些患者在基线时通过心血管磁共振(CMR)和斑点追踪超声心动图进行了多模态成像评估。12个月的随访包括对RV FW-GLS和RV-PA耦联的超声心动图评估。RV逆向重构定义为RV FW-GLS和/或RV-PA耦联较基线改善>10%。使用三尖瓣环平面收缩期位移/肺动脉收缩压(TAPSE/PASP)比值评估RV-PA耦联。:在12个月的他法米地治疗期间,22.6%的患者出现了RV逆向重构。在这些患者中,RV FW-GLS从14.5±2.1%显著改善至17.3±2%,<0.001,而TAPSE/PASP比值从0.42±0.05毫米/毫米汞柱改善至0.54±0.07毫米/毫米汞柱,=0.001。经历RV逆向重构的患者在接受他法米地治疗前处于疾病早期,RV扩张程度较小,RV-PA解耦程度较轻(TAPSE/PASP比值:0.43±0.06毫米/毫米汞柱对0.39±0.06毫米/毫米汞柱,=0.040)。CMR得出的基线右心室收缩末期容积(HR 0.83,95%CI 0.73 - 0.94,=0.005)和N末端B型利钠肽原(HR 0.989,95%CI 0.988 - 0.999,=0.024)是RV逆向重构最强的独立预测因素,其次是肺动脉收缩压(HR 0.82,95%CI 0.69 - 0.98,=0.030)。:在疾病早期接受他法米地治疗的ATTR-CM患者经历了RV逆向重构,RV FW-GLS和RV-PA耦联有显著改善。